

The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis*

Received for publication, July 7, 2014, and in revised form, August 22, 2014. Published, JBC Papers in Press, September 10, 2014, DOI 10.1074/jbc.M114.594861

John S. Chorba^{‡§1} and Kevan M. Shokat^{§¶1}

From the [‡]Division of Cardiology, San Francisco General Hospital, Department of Medicine, University of California, San Francisco, California 94110, [§]Cardiovascular Research Institute, University of California, San Francisco, California 94158, and [¶]Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California 94158 and Department of Chemistry, University of California, Berkeley, California 94720

Background: PCSK9 inhibition shows promise in the treatment of hypercholesterolemia and prevention of atherosclerotic heart disease.

Results: PCSK9 proteolysis and secretion have different structural requirements near the protein active site.

Conclusion: PCSK9 proteolysis and secretion occur in two separate steps.

Significance: The PCSK9 active site can serve as an allosteric modulator of protein secretion, suggesting a new strategy for inhibition.

Biologic-based strategies to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) show promise as anti-hypercholesterolemic and, therefore, anti-atherosclerotic therapies. Despite substantial effort, no small molecule strategy to inhibit PCSK9 has demonstrated feasibility. In this study we interrogated the chemistry of the PCSK9 active site and its adjacent residues to identify a foothold with which to drug the PCSK9 processing pathway and ultimately disrupt the interaction with the LDL receptor. Here, we develop a system in which we amplify the readout of PCSK9 proteolysis with a highly specific substrate in cells, showing that the PCSK9 catalytic domain is capable of proteolysis *in trans*. We use this system to show that the substrate specificity for PCSK9 proteolysis is distinct from the specificity for PCSK9 secretion, demonstrating that PCSK9 processing occurs in two separate sequential steps: that of proteolysis followed by secretion. We show that specific residues in the protease recognition sequence can differentially modulate the effects on proteolysis and secretion. Additionally, we demonstrate that the clinically described, dominant negative Q152H mutation restricts proteolysis and secretion independently. Our results suggest that the PCSK9 active site and its adjacent residues serve as an allosteric modulator of protein secretion independent of its role in proteolysis, revealing a new strategy for intracellular PCSK9 inhibition.

Proprotein convertase subtilisin/kexin type 9 (PCSK9)² binds to the LDL receptor (LDL-R) on the hepatocyte cell surface, targeting it for lysosomal degradation (1, 2). By decreasing the available LDL-R, PCSK9 causes serum LDL cholesterol to increase, promoting atherosclerosis and heart disease (3). Due to a wealth of robust genetic data (4–7) and a well elucidated biochemical mechanism (8–11), PCSK9 has become a well validated target to treat hypercholesterolemia and, by extension, prevent atherosclerotic heart disease. Indeed, multiple strategies to inhibit the function of PCSK9 have reached clinical proof-of-principle (12–15). However, no small molecule approach is among them.

Although a small molecule strategy to inhibit PCSK9 is highly desirable, the cellular life cycle of PCSK9 offers insight into the challenge that small molecules face. Biochemically, PCSK9 is a protease, and the presence of an active site suggests it is a tractable drug target. However, among proteases it is unusual; its only known target is itself, and it undergoes only a single-turnover reaction. Proper self-cleavage, however, is critical for its function; after translocation to the endoplasmic reticulum (ER) and removal of the signal sequence, the proPCSK9 species undergoes intramolecular proteolysis. The cleaved, mature PCSK9 is trafficked through the *trans*-Golgi network and secreted into the extracellular space (Fig. 1A) where it reaches its target, the LDL-R (16–19). Because PCSK9 proteolysis is necessary for proper secretion (Fig. 1, A and B) (18, 20) and subsequently the extracellular interaction with the LDL-R, inhibiting proteolysis has been proposed as a therapeutic strategy. However, this approach has been remarkably difficult to achieve (15, 21). After self-proteolysis, the C terminus of the prodomain remains non-covalently bound to the active site

* This work was supported, in whole or in part, by National Institutes of Health Grants F32 HL116189 and LRP HMOT1243 (to J. S. C.). This work was also supported by American Heart Association Grant 12POST11360011 (to J. S. C.), a Gilead Sciences Research Scholar in Cardiovascular Sciences Award (to J. S. C.), and the Howard Hughes Medical Institute (to K. M. S.).

¹ To whom correspondence should be addressed: Division of Cardiology, San Francisco General Hospital, Dept. of Medicine, University of California, San Francisco, 600 16th St., San Francisco, CA 94158-2280. Tel.: 415-502-1475; Fax: 415-514-0822; E-mail: john.chorba@ucsf.edu.

² The abbreviations used are: PCSK9, proprotein convertase subtilisin/kexin type 9; LDL-R, LDL receptor; CHR, cysteine-histidine rich; ER, endoplasmic reticulum; Ni-NTA, nickel nitrilotriacetic acid; Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; SS, signal sequence; Cat, catalytic.

and is thought to act as a self-inhibitor, preventing any further proteolytic activity (22). *In vitro* methods of measuring PCSK9 proteolytic activity struggle from the low intrinsic activity of the protease, requiring high amounts of purified protein and producing low signal-to-noise ratios (23). In addition, the prodomain cannot be removed from the catalytic domain short of denaturing the entire protein, and no group has isolated the proteolytically active proPCSK9 form (24). Last, even if an inhibitor for the PCSK9 protease was found, it would likely need to outcompete an intramolecular reaction to be clinically useful.

Chemical challenges are not atypical for protease inhibitors. Direct renin inhibitors serve as an example that these challenges can be overcome; after decades of focused effort, a structure and modeling approach produced aliskiren, now a clinically approved compound (25, 26). Our understanding of PCSK9 processing and maturation suggests that the difficulty in targeting PCSK9 proteolysis is primarily one of active site accessibility. We thus undertook the present study to thoroughly investigate the biochemistry of the PCSK9 active site. Our primary goal was to identify any unusual aspects that would allow us a foothold into a possible small molecule approach to perturb PCSK9 proteolysis or secretion.

EXPERIMENTAL PROCEDURES

Materials and Reagents—Oligonucleotide primers were custom synthesized by Elim Biopharmaceuticals (Hayward, CA). Restriction enzymes and polymerases were purchased from New England Biolabs (Ipswich, MA). Mouse monoclonal antibodies to FLAG (clone M2) and V5 (clone V5-10) and anti-FLAG M2 magnetic beads were obtained from Sigma. Mouse monoclonal antibody to penta-His and Ni-NTA-agarose were obtained from Qiagen (Valencia, CA). Mouse monoclonal antibody to β -actin (8H10D10), rabbit monoclonal antibody to GFP (D5.1 XP), which also detects cyan and yellow fluorescent protein, goat anti-rabbit IgG HRP-conjugate antibody, and horse anti-mouse IgG HRP-conjugate antibody were all obtained from Cell Signaling (Danvers, MA). Rabbit polyclonal antibody to transferrin was obtained from Enzo Life Sciences (Farmingdale, NY). Goat anti-mouse IgG IRDye 800CW conjugate and goat anti-rabbit IgG IR Dye 800CW conjugate were obtained from LI-COR Biotechnology (Lincoln, NE).

Plasmid Construction—PCSK9 expression vectors were created by PCR amplification of the appropriate PCSK9 domains from pCMV-PCSK9-FLAG (generously provided by Prof. J. Horton, UT Southwestern) with custom oligonucleotides and subsequent cloning into the BglII and NotI restriction sites of pIRES2-AcGFP1 and pIRES2-DsRed2 (Clontech, Mountain View, CA). V5, HA, and His₆ tags, VFAQSIP insertions, and single site mutations were added by site-directed mutagenesis using partially overlapping primers to generate the constructs as shown in the schematics (27). Truncations of the prodomain C terminus, prodomain, and removal of the vector sequence encoding the fluorescent proteins were also performed by site-directed mutagenesis using partially overlapping primers. Expression vectors encoding FRET substrates were created by Gibson assembly (28) after PCR amplification of CyPET and YPET from pB33-newCyPET-LVPRGS(Sub)-YPET (gener-

ously provided by Dr. T. Shropshire and Prof. P. Daugherty, UC Santa Barbara) and using the PCSK9 expression vectors as a backbone. All plasmids were extensively sequenced to confirm their identities.

Mammalian Cell Culture and Transfections—HEK293T cells (ATCC, Manassas, VA) were cultured in DMEM with 10% FBS. Cells were plated in 6-well plates coated with poly-L-lysine (Sigma) 1 day before transfection to obtain ~50–75% confluency at the time of the experiment. Cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions using 0.5 μ g of DNA per construct. The medium was changed 6–8 h after transfections; for samples in which the conditioned media was evaluated the medium was changed to DMEM with 1 \times insulin-transferrin-selenium (Invitrogen) rather than DMEM with 10% FBS. After 48–72 h post-transfections, the cells and conditioned media (if appropriate) were harvested for Western blot analyses. The conditioned media was centrifuged for 5 min at 1000 \times g, and the resulting supernatant was concentrated ~10 \times using Amicon Ultra 10 kDa protein concentrators (EMD Millipore, Billerica, MA). The cells were washed twice with ice-cold PBS, lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Nonidet P-40, 0.5% Triton X-100) for 10 min, and then clarified at 21,000 \times g for 15 min. Protein concentration was analyzed by Bradford assay (Bio-Rad). Gel samples were prepared with a SDS-based loading buffer under reducing conditions and heated at 98 $^{\circ}$ C for 5 min. All transfection experiments were repeated at least three times to ensure reproducibility.

Ni-NTA Pulldown Assays—Conditioned media from transfections was adjusted to pH 8.0 with Tris-HCl to a final concentration of 50 mM, and imidazole was added to a final concentration of 10 mM. The medium was centrifuged at 1000 \times g, and the supernatant was added to Ni-NTA-agarose beads (Qiagen) previously equilibrated in binding buffer (20 mM Tris-HCl, pH 8.0, 250 mM NaCl, and 10 mM imidazole). Medium was batch-bound for 4 h with rotation at 4 $^{\circ}$ C. The beads were washed 3 times with 10 \times volumes of wash buffer (20 mM Tris-HCl, pH 8.0, 250 mM NaCl, 20 mM imidazole). Elution was performed with 5 \times volumes of elution buffer (20 mM Tris-HCl, pH 8.0, 250 mM NaCl, 250 mM imidazole) with the supernatant saved and the process repeated. The fractions were pooled and concentrated ~10 \times in Amicon Ultra 10-kDa concentrators. The concentrated samples were then prepared for gel analysis using a SDS-based loading buffer under reducing conditions and heated at 98 $^{\circ}$ C for 5 min.

Anti-FLAG Immunoprecipitations—Transfected cells were lysed on ice for 10 min in lysis buffer containing a protease inhibitor mixture (Roche Applied Science) and clarified at 21,000 \times g for 15 min. The resultant supernatant was saved and subjected to Bradford assay. Equivalent amounts of lysate (according to total protein) were added to anti-FLAG M2 magnetic beads (Sigma) previously equilibrated in lysis buffer and bound at 4 $^{\circ}$ C with rotation overnight. The beads were then washed 3 times with 10 \times volumes of lysis buffer and once with 10 \times volumes of TBS. Elution was performed by incubation with 10 \times volumes of 0.1 M glycine, pH 3.0, at room temperature with rotation for 5 min. The process was repeated, and the elution fractions were pooled and concentrated ~10 \times in Ami-

Role of the PCSK9 Active Site in Proteolysis and Secretion

can Ultra 10-kDa concentrators. The concentrated samples were then prepared for gel analysis using a SDS-based loading buffer under reducing conditions and heated at 98 °C for 5 min.

Western Blot Analyses—Gel samples were loaded onto 4–12% Bis-Tris SDS NuPAGE precast gels (Invitrogen) for electrophoresis. The size-separated proteins were then transferred to nitrocellulose. The blots were blocked in 5% nonfat dry milk in Tris-buffered saline (20 mM Tris, pH 7.4, 150 mM NaCl) containing 0.1% Tween (TBS-T) for 1 h. The appropriate primary antibodies were hybridized to the blots overnight at 4 °C. The blots were washed 3 times for 10 min each with TBS-T, and the appropriate secondary antibodies were hybridized in 5% nonfat dry milk in TBS-T for 1 h at room temperature. The blots were again washed 3 times for 10 min each with TBS-T before either developing with chemiluminescent substrate and imaging with CL-Xposure film (Thermo Fisher Scientific, Rockford, IL) or directly imaging with the ODYSSEY infrared imaging system (LI-COR Biotechnology, Lincoln, NE). Quantification was performed with the LI-COR Image Studio or Image Studio Lite software.

RESULTS

The PCSK9 Catalytic Domain Can Perform Intermolecular Proteolysis—We first endeavored to develop a robust method to evaluate PCSK9 proteolysis. To maximize both utility and specificity in our system, we focused on proteolysis in the native, cellular environment with a highly specific substrate. Although conversion of wild-type proPCSK9 to mature PCSK9 occurs in an intramolecular fashion (Fig. 1A) (17), McNutt *et al.* (29) demonstrated that the prodomain and catalytic domain can be assembled *in trans* (*i.e.* as two separate polypeptides), which effectively bypasses the need for proteolysis and does not require intrinsic proteolytic activity (Fig. 1, C and D). Furthermore, a secretion-defective PCSK9 mutant can transfer its prodomain to a prodomain-deficient (and also secretion-defective) PCSK9, rescuing the secretion of the latter PCSK9 species (30). As such, we hypothesized that the *in trans* assembly of the catalytic domain and a specific substrate and subsequently intermolecular proteolysis could also occur.

To evaluate this hypothesis, we designed a series of constructs to evaluate for the specific cleavage of a “substrate,” a full-length but proteolytically inactive S386A mutant PCSK9 termed substrate_{PCSK9}, by a “protease,” an orthogonally tagged PCSK9 construct containing the catalytic domain (Fig. 2A). Given that the S386A mutant is devoid of proteolytic activity, any cleavage of the substrate in our system must, therefore, come from an intermolecular cleavage event. Similarly, we used the S386A mutant in each protease construct throughout our investigation as a negative control. Co-transfection of a full-length PCSK9 protease, termed protease_{PCSK9}, with substrate_{PCSK9} into HEK 293T cells revealed a trace amount of cleaved substrate_{PCSK9} in the lysate (Fig. 2B, lane 4, open arrows). By contrast, co-transfection of the inactive protease_{PCSK9-S386A} with substrate_{PCSK9} produced no cleavage product (Fig. 2B, lane 5). Consistent with prior studies concluding that the vast majority of PCSK9 proteolysis is intramolecular (16, 17), the scale of intermolecular cleavage seen with protease_{PCSK9} was far below (only ~1%) that of intramolecular




FIGURE 1. Schematics of PCSK9 processing. The known processing pathways of PCSK9 are shown. The signal sequence is shown in dark gray, the prodomain in red, the catalytic domain in light gray, and the CHR domain in blue. *A*, processing of wild-type PCSK9. The nascent PCSK9 polypeptide is directed to the ER by a signal sequence, which is subsequently removed by a signal peptidase. The proPCSK9 form then undergoes auto-proteolysis, and the mature, cleaved form is transported to the *trans*-Golgi network (TGN) via a COPII complex involving Sec24a. Secretion from the *trans*-Golgi network is facilitated by sortilin. The PCSK9 binds the LDL-R on the cell surface, chaperoning the receptor for lysosomal degradation upon internalization. *B*, processing of proteolytically inactive PCSK9. PCSK9 with an active site mutation (S386A) cannot perform intramolecular proteolysis, is retained in the ER, and thus cannot interact with the LDL-R on the cell surface. *C*, processing of *in trans* PCSK9. In an experimental system the prodomain and prodomain-deficient catalytic and CHR domains are expressed as separate polypeptides, each directed independently to the ER. These domains assemble *in trans*, bypassing the proteolytic step to form a mature PCSK9 that follows the remainder of the prototypic processing pathway and retains activity against the LDL-R. *D*, processing of *in trans* proteolytically inactive PCSK9. Because the proteolytic step is bypassed, a proteolytically inactive PCSK9 can be assembled *in trans* and secreted, retaining activity against the LDL-R.

cleavage of wild-type PCSK9 (Fig. 2, B, lane 2 compared with lane 4, and D, left, blue). However, the co-transfection of a prodomain-deficient protease, termed protease_{PCSK9ΔPro}, markedly increased cleavage of substrate_{PCSK9} (Fig. 2B, lane 6) when compared with protease_{PCSK9} (Fig. 2B, lane 4) to just >15% of our wild-type benchmark (Fig. 2D, right, blue). In addition, the absence of cleaved substrate_{PCSK9} with the co-transfection of inactive protease_{PCSK9ΔPro-S386A} (Fig. 2B, lane 7) shows that the proteolysis of substrate_{PCSK9} is highly specific for the active protease_{PCSK9ΔPro}. Furthermore, because protease_{PCSK9ΔPro} is significantly more active than protease_{PCSK9}, these data show that the prodomain is a *cis*-acting inhibitor of intermolecular proteolysis, consistent with the known PCSK9 structure (22, 24, 31). We were particularly encouraged by our ability to amplify the detection of intermolecular PCSK9 proteolysis, especially given that the PCSK9 protease is thought to only undergo a single turnover event.

We then sought to evaluate whether the processed intermolecular cleavage products were properly secreted like wild-type PCSK9. To do so we evaluated the conditioned media of our co-transfections by Western blot (Fig. 2C, left). Secretion of protease_{PCSK9ΔPro} occurred only in the presence of sub-




FIGURE 2. The PCSK9 catalytic domain can perform proteolysis *in trans*. *A*, schematics of the PCSK9 expression constructs. All PCSK9 expression constructs contain the N-terminal signal sequence and the appropriate PCSK9 domains as labeled. Domains within constructs are colored to correspond to the C-terminal recognition tag, orthogonal between protease and substrate constructs: *magenta*, V5 (N-terminal, substrate); *green*, FLAG (C-terminal, substrate); *orange*, His (C-terminal, protease). The P5 through P4' sequence spanning the transition from the prodomain to catalytic domain is shown in wild-type PCSK9, substrate_{PCSK9}, and protease_{PCSK9}, with the cleavage site indicated by the *arrowhead*. The S386A mutation in substrate_{PCSK9} is shown. *B*, Western blots (WB) of cell lysates from co-transfections of constructs or empty vectors into 293T cells as indicated. Wild-type PCSK9 (*lane 2*) serves as the positive control. Uncleaved substrate is noted by the *black arrow*. Cleavage products of substrate_{PCSK9} are noted by the *open arrows*. *C*, Western blots of conditioned media (*left*) and Ni-NTA pulldown assays (*right*) from the same experiment as in *B*. *D*, mean levels of processed substrate_{PCSK9} from either proteolysis (*blue*) or secretion (*purple*), as normalized to intramolecular proteolysis or secretion of wild-type PCSK9, respectively, from three independent experiments. *Error bars* represent S.E. *E*, model for processing of intermolecularly cleaved PCSK9. Protease_{PCSK9ΔPro} recognizes the prodomain of substrate_{PCSK9} in the ER in a manner akin to *in trans* assembly, performs intermolecular proteolysis, and then retains the "donor" prodomain from substrate_{PCSK9}. Protease_{PCSK9ΔPro}, with its donor prodomain, is capable of secretion following the prototypic PCSK9 secretion pathway, whereas the C-terminal cleavage product of substrate_{PCSK9}, without its prodomain, is retained in the ER. TGN, *trans*-Golgi network.

substrate_{PCSK9} and was accompanied by the prodomain from substrate_{PCSK9} (Fig. 2*C*, *left*, *lane 6*) to levels of ~10% that of wild-type PCSK9 (Fig. 2*D*, *right*, *purple*). By contrast, the inactive protease_{PCSK9ΔPro-S386A} was not secreted in the presence of substrate_{PCSK9} (Fig. 2*C*, *left*, *lane 7*). A trace amount (<1% of

wild type) of prodomain from substrate_{PCSK9} was also secreted with protease_{PCSK9} (Fig. 2*C*, *left*, *lane 4*, and Fig. 2*D*, *left*, *purple*). The C-terminal cleavage product of substrate_{PCSK9}, which contains the catalytic and cysteine-histidine-rich (CHR) domains, was not secreted under any condition (Fig. 2*C*, *left*).

Role of the PCSK9 Active Site in Proteolysis and Secretion

To confirm the association of the V5-tagged prodomain with the His-tagged protease_{PCSK9ΔPro}, we performed a pulldown experiment with Ni-NTA-agarose beads on the conditioned media to isolate the His-tagged protease_{PCSK9} and protease_{PCSK9ΔPro}. This showed that the prodomain from substrate_{PCSK9} co-precipitated with both proteases (Fig. 2C, right, lanes 4 and 6). Furthermore, there was proportionally much greater V5-tagged prodomain with protease_{PCSK9ΔPro} than with protease_{PCSK9} (Fig. 2C, right, compare lane 6 to lane 4). This likely results from a preference of protease_{PCSK9} to utilize its own prodomain for secretion, which protease_{PCSK9ΔPro} lacks. Overall, these data suggest that the prodomain is retained by the protease_{PCSK9ΔPro} after intermolecular cleavage and are consistent with a model whereby the protease_{PCSK9ΔPro} assembles with the prodomain of substrate_{PCSK9}, performs intermolecular cleavage, and then non-covalently retains the prodomain in a manner akin to intramolecularly processed PCSK9 (Fig. 2E). The prodomain from substrate_{PCSK9} then serves as the chaperone guiding the mature protease_{PCSK9ΔPro} out of the ER through the Golgi and ultimately to the extracellular space. Despite undergoing cleavage, the catalytic and CHR domains of substrate_{PCSK9} have been stripped of their own prodomain and thus are not secreted.

The Scope of Intermolecular PCSK9 Proteolysis Is Narrow—Having identified an optimized, highly specific substrate for protease_{PCSK9ΔPro}, we next addressed the scope of the intermolecular cleavage reaction, as knowledge of the substrate specificity is an important first step toward inhibitor design. We asked whether the known cleavage sequence could be recognized and cut if placed elsewhere within the prodomain, anticipating that such engineering might generate a more active protease. We posed this hypothesis based on the typical processing pathway of proprotein convertases; most members of this family of proteases undergo two cleavage events to mature (32). The first event, common to all convertases including PCSK9, cuts the prodomain from the catalytic domain, allowing the prodomain to serve both as a chaperone for delivery of the convertase to its proper cellular compartment and a self-inhibitor of proteolytic activity (33). The second event, which PCSK9 does not perform, cleaves the prodomain at the flexible L loop, causing the prodomain to dissociate from the active site, releasing the self-inhibition on the proteolytic activity of the convertase (34). We, therefore, interrogated the small L loop of PCSK9, located after Lys-125, as well as an additional solvent-exposed loop of the prodomain at Pro-138 to evaluate whether an additional proteolytic event could occur. We inserted the seven-amino acid PCSK9 cleavage sequence VFAQSIP into our initial substrate construct between Lys-125 and Met-126 to create substrate_{PCSK9-K125iSELF} and in place of Pro-138 and His-139 to create substrate_{PCSK9-P138iSELF} (Fig. 3A). Co-transfection of substrate_{PCSK9-K125iSELF} with protease_{PCSK9ΔPro} revealed only a trace amount of cleaved product (Fig. 3B, left, open arrows, lane 3) with cleavage clearly less efficient than with unmodified substrate_{PCSK9} (Fig. 3B, left, lane 2). Because of the low signal for cleavage of substrate_{PCSK9-K125iSELF} in the lysates, we confirmed the presence of the N-terminal cleavage product in the conditioned media (Fig. 3B, right, open arrow, lane 3), indicating that it also permit-

ted secretion of the protease. Importantly, this cleavage product migrated at ~18 kDa and just above the prodomain of the unmodified substrate_{PCSK9}, consistent with a cleavage site at the native Gln-152 (anticipated molecular mass of ~17 kDa) rather than within the engineered sequence (anticipated molecular mass of ~13 kDa) (Fig. 3B, compare lanes 2 and 3). We did not detect a band at a lower molecular weight corresponding to the smaller cleavage product, indicating that cleavage within the engineered insertion sequence did not occur. By contrast, neither appreciable cleavage nor secretion of the protease occurred for substrate_{PCSK9-P138iSELF} (Fig. 3B, lane 5) or for any conditions with inactive protease_{PCSK9ΔPro-S386A} (Fig. 3B, lanes 4 and 6), indicating that the insertion in place of Pro-138/His-139 also prevented proteolysis of the native sequence. Because our insertions were purposefully non-conservative, we acknowledge that such mutagenesis may have disrupted the proper folding of the substrate_{PCSK9}, preventing it from forming a cleavable complex with protease_{PCSK9ΔPro}. However, because the complex of protease_{PCSK9ΔPro} and the prodomain from substrate_{PCSK9-K125iSELF} permits secretion, we know this is unlikely for this particular insertion. Although we cannot rule out the possibility that a VFAQSIP site placed elsewhere within the prodomain would be cleaved, our data show that the catalytic domain cannot identify and cleave its known recognition site when that site is placed within the prodomain L loop.

To further address the scope of this reaction, we next asked whether the PCSK9 catalytic domain could identify and cleave a minimal recognition sequence outside of the full PCSK9 protein. We generated minimal substrates consisting of the anticipated PCSK9 cleavage sequences VFAQSIPW and SSVFAQSIPWNL flanked by a fluorescent protein pair (CyPET-YPET) (35). Co-expression of either substrate with protease_{PCSK9ΔPro} revealed no appreciable cleavage product (data not shown), suggesting that the catalytic domain requires at least another region of substrate_{PCSK9} beyond the cleavage site itself to properly recognize and cleave its known sequence. When taken together with the results of Fig. 3, these data support the concept that the PCSK9 catalytic domain has a narrow specificity window for its known substrate.

The Prodomain Inhibits Intermolecular Proteolysis in trans, Dependent on Its C-terminal Tail—Having established both the capability and the relatively narrow scope of the PCSK9 catalytic domain for intermolecular cleavage, we next sought to identify a positive control for an inhibitor of the intermolecular proteolysis reaction. Based on the occupancy of the active site by the prodomain C terminus (22, 24, 31) as well as our own results of the prodomain inhibiting intermolecular proteolysis in *cis*, we hypothesized that exogenous prodomain would serve as a model inhibitor and effectively block intermolecular proteolysis in *trans*. To test this we performed co-transfections in the intermolecular cleavage system (protease_{PCSK9ΔPro} acting upon substrate_{PCSK9}) with an additional wild-type prodomain construct termed prodomain_{WT} (Fig. 4A). Co-transfection of protease_{PCSK9ΔPro} with substrate_{PCSK9} and prodomain_{WT} revealed progressively less cleaved substrate with increasing




FIGURE 3. The catalytic domain cannot cleave an engineered substrate sequence placed in the prodomain L loop. A, schematics of the PCSK9 expression constructs. Domains tracking with the C-terminal tags are shown in the corresponding color: *magenta*, V5 (N-terminal, substrate); *orange*, His (C-terminal, substrate); *green*, FLAG (C-terminal, protease). A VFAQSIP substrate sequence is inserted between Lys-125 and Met-126 for substrate_{PCSK9-K125ISELF} and in place of Pro-138 and His-139 for substrate_{PCSK9-P138ISELF}. The native VFAQSIP PCSK9 cleavage sequence in both substrates remains intact as shown. The expected cleavage sites are noted by the *arrowheads*. B, Western blots (WB) of cell lysates (*left*) and conditioned media (*right*) of co-transfections with the indicated constructs. Unmodified substrate_{PCSK9} with protease_{PCSK9ΔPro} (*lane 2*) serves as the positive control. Note that the V5-tagged N-terminal cleavage product of substrate_{PCSK9-K125ISELF} migrates at a slightly greater molecular weight than that of substrate_{PCSK9}, indicating that the cleavage site is at the native Gln-152 rather than the engineered VFAQSIP sequence between Lys-125 and Met-126.

expression levels of the prodomain_{WT} (Fig. 4B, lanes 4–7, and the graph below).


We next wished to carry out a structure-activity relationship study of the determinants of inhibition by the C-terminal tail of the prodomain. We created a series of mutant prodomain constructs harboring progressive amino acid deletions from the C terminus. We extended our truncations through the six amino acids spanning the entire binding groove of the active site, from the terminal Gln-152 to Ser-147, to create constructs prodomain_{Δ152} through

prodomain_{Δ147} (Fig. 4A). As anticipated, we found that at equivalent expression levels, the wild-type prodomain was the most effective inhibitor of intermolecular proteolysis (Fig. 4C, lane 4). Furthermore, the loss of even one amino acid from the C terminus markedly abrogated the inhibitory ability of the exogenous prodomain, as evidenced by the presence of more cleavage product (Fig. 4C, compare lane 5 to lane 4, and the graph below). Importantly, further truncations did not result in progressively less effective inhibitors (Fig. 4C, lanes 6–10, and the graph below).

Role of the PCSK9 Active Site in Proteolysis and Secretion

The Prodomain C Terminus Regulates Protein Secretion but Is Not Required for Catalytic Domain Binding—One potential explanation for these results is that the entire prodomain is required to bind to the catalytic domain and inhibit the

intermolecular cleavage reaction. To evaluate this, we co-transfected our truncated prodomain Δ constructs with protease_{PCSK9 Δ Pro} to evaluate for the proper association of these domains in cells. Anti-FLAG immunoprecipitations of



Role of the PCSK9 Active Site in Proteolysis and Secretion

However, the tolerability at Phe-150 is somewhat surprising given that the phenyl ring of this side chain makes a π - π stacking interaction with the indole of Trp-72 and is important for proper intramolecular cleavage of PCSK9 (16, 22).

We were intrigued by the differential structural requirements of the proteolytic site *vis à vis* the requirements for secretion *in trans* in a system that effectively bypasses the need for proteolysis. We next performed a serial alanine scan of the P5 through P4' residues of substrate_{PCSK9} to determine the tolerance for these mutations in our intermolecular cleavage system. Co-transfections of protease_{PCSK9 Δ Pro} with the substrate_{PCSK9} alanine scan mutants revealed that alanine substitutions at most positions were well tolerated, with the exception of P4 (Val-149) and P3 (Phe-150), where no cleavage occurred (Fig. 6, B and C). The intolerance for intermolecular cleavage for V149A was not surprising given prior work showing that this mutation abolishes intramolecular proteolysis (16) as well as our own results indicating that this mutation did not permit secretion. However, the lack of intermolecular cleavage of our F150A mutant was unexpected, as this mutant is known to permit a low level of intramolecular proteolysis (16). In addition, our results showed that the F150A modestly permitted secretion in the *in trans* system, highlighting the disconnect between secretion and intermolecular proteolysis. Overall, our data show that the F150A mutant is incapable of intermolecular proteolysis, but if such proteolysis is bypassed then the F150A mutant is capable of secretion. This also suggests that, at least for our intermolecular system, the process of secretion of mature PCSK9 from the ER does not occur in a one-step concerted mechanism with proteolysis but instead involves two separate events mediated by different complexes (*i.e.* proteolysis, followed by secretion).

Having identified differential prodomain requirements for secretion and intermolecular proteolysis, we desired to return to a physiologic system that would mimic a natural PCSK9 variant and look for a similar disconnect between secretion and intramolecular proteolysis. We thus focused on Gln-152 given that the Q152H mutation has been documented in a patient cohort as a dominant-negative, loss-of-function phenotype resulting in low serum LDL cholesterol and a reduced incidence of atherosclerotic heart disease (36, 37). We began with a vertical mutagenesis strategy at Gln-152 to evaluate the requirements on secretion, as others have demonstrated the requirement of Gln-152 on intramolecular proteolysis previously (37). We generated a series of Q152X mutations in our prodomain constructs and performed co-transfections of prodomain_{Q152X} with protease_{PCSK9 Δ Pro}. Comparing the mutations that permitted secretion in our strategy (Fig. 7) to prior reports of mutations permitting proteolysis (37), we identified four phenotypes of residues according to the independent effects on proteolysis and secretion. We then installed representative mutations in both full-length PCSK9 and our substrate_{PCSK9} constructs to confirm the effects of these mutations on both intra- and intermolecular proteolysis and test alongside secretion. Fig. 8B shows the results of intramolecular proteolysis of the full-length PCSK9_{Q152X} (*left*) and intermolecular proteolysis from protease_{PCSK9 Δ Pro} on substrate_{PCSK9-Q152X} (*right*), whereas Fig. 8C shows the results of secretion from the *in trans* assembly of




FIGURE 6. An alanine scan of the substrate cleavage sequence reveals that Val-149 and Phe-150 are critical for proteolysis. A, schematics of the expression constructs are shown. The P5 through P4' cleavage site residues spanning the prodomain/catalytic domain interface of substrate_{PCSK9} are illustrated, with those targeted for alanine mutation *underlined*. B, Western blots (WB) of cell lysates of co-transfections of protease and substrate constructs as indicated. Uncleaved product is noted by the *black arrow*. Products of specific cleavage by protease_{PCSK9 Δ Pro} are noted by the *open arrow*. A non-specific cleavage product of substrate_{PCSK9} is noted by the *gray arrow*. Co-transfection of unmodified substrate_{PCSK9} with protease_{PCSK9 Δ Pro} serves as the positive control (*lane 3*). C, relative cleavage of substrate_{PCSK9} alanine scan mutants normalized to wild-type substrate_{PCSK9} from two orthogonal readouts from two independent experiments. Error bars represent S.E.

protease_{PCSK9 Δ Pro} and prodomain_{Q152X}. As expected, the wild-type residue permitted both intra- and intermolecular proteolysis (Fig. 8B, *lane 2*) as well as secretion when expressed *in trans* (Fig. 8C, *lane 2*). The clinically relevant Q152H mutation permitted some proteolysis in both systems, albeit markedly less efficiently than the wild-type (Fig. 8, B, *lane 3*, and D, *light and dark blue*), and was also markedly limited in secretion (Fig. 8, C, *lane 3*, and D, *purple*). The block on secretion, however, was not absolute, as secretion of Q152H (as well as for Q152I) was mildly improved when the mutant prodomain was co-ex-




FIGURE 7. Vertical mutagenesis strategy showing the importance of residue 152 in mediating secretion. *A*, schematics of the expression constructs are shown. The C-terminal residues of the prodomain are illustrated for clarity, highlighted by the Q152X mutation in yellow, with the identity of the individual Q152X mutations noted in the subsequent blots. *B*, Western blots (WB) of cell lysates (*top*) and conditioned media (*bottom*) of co-transfections with the indicated protease and prodomain constructs. Co-transfection of protease_{PCSK9ΔPro} with the wild-type prodomain serves as the positive control (*lane 4*). *C*, relative secretion of the protease_{PCSK9ΔPro}-prodomain complex for Q152X mutant, normalized to wild-type in *trans* PCSK9. Data are from two orthogonal readouts from two independent experiments, and error bars represent S.E.

pressed with the inactive protease_{PCSK9ΔPro-S386A} as compared with the active protease_{PCSK9ΔPro} (Fig. 8C, compare lanes 3 and 4 with lanes 7 and 8). The Q152I mutation completely abrogated proteolysis in both intra- and intermolecular systems (Fig. 8, *B*, *lane 4*, and *D*) but had only a limited impact on secretion (Fig. 8, *C*, *lane 4*, and *D*, purple). The Q152R mutation completely abolished both proteolysis and secretion (Fig. 8, *B* and *C*, *lanes 5*, and *D*). The phenotypes of these mutations

are summarized by the schematic in Fig. 8E. Although each of the mutations was less permissive for either proteolysis or secretion as compared with the wild type, the illustrative finding is that certain mutations have differential effects on these two processes. These findings lend further support to our conclusion that proteolysis and secretion proceed in two independent steps mediated by different structural requirements.

Role of the PCSK9 Active Site in Proteolysis and Secretion




FIGURE 8. The four phenotypes of Q152X mutants. *A*, schematics of the expression constructs are shown grouped by experiments. Note that the protease constructs with His tags (orange) correspond to intermolecular proteolysis experiments, and those with FLAG tags (green) correspond to *in trans* secretion experiments. The Q152X mutations in the PCSK9, substrate_{PCSK9}, and prodomain constructs are highlighted in yellow. *B*, Western blots (WB) of cell lysates (top) and conditioned media (bottom) from co-transfections with PCSK9 constructs (intramolecular proteolysis, left) and protease and substrate constructs (intermolecular proteolysis, right). Uncleaved product is noted by the black arrow, nonspecific cleavage product by the gray arrow, and N- and C-terminal cleavage products noted by the open arrows, respectively. The wild-type Gln-152 serves as the positive control in all experiments (lane 2). *C*, Western blots of cell lysates (top) and conditioned media (bottom) from co-transfections with PCSK9 constructs of protease and prodomain constructs (*in trans* secretion). *D*, relative levels of intramolecular proteolysis (light blue), intermolecular proteolysis (dark blue), or *in trans* secretion (purple) of the Q152X mutants in the corresponding experimental system, normalized to the wild-type Gln-152. Data are from three independent experiments, and error bars represent S.E. *E*, schematic illustrating the phenotypes of the Q152X mutants with regard to permission of proteolysis (either intra- or intermolecular) or isolated effect on secretion (in the *in trans* system, with proteolysis bypassed). The wild-type glutamine permits both proteolysis and secretion, the histidine mutant permits some proteolysis but mainly precludes secretion, the isoleucine mutant precludes proteolysis but permits secretion, and the arginine mutant precludes both proteolysis and secretion.

DISCUSSION

In this study we began with a desire to learn more about the chemistry of the PCSK9 active site in an attempt to gain a foothold onto a highly validated therapeutic target considered too challenging to drug by binding a small molecule into the active site. We found that the PCSK9 catalytic domain has the capac-

ity to perform intermolecular proteolysis on a highly specific substrate, an orthogonally tagged but catalytically inactive proPCSK9 molecule. Furthermore, we found that such cleavage with our protease_{PCSK9ΔPro} construct was more efficient when compared with the cleavage performed by wild-type PCSK9, allowing our assay to effectively amplify the readout of intermo-

lecular PCSK9 proteolysis. We suspect that further development of this assay may be particularly useful in future screening strategies aimed at identifying small molecules or genetic targets that inhibit PCSK9 proteolysis as an ultimate means of inhibiting PCSK9's hypercholesterolemic effect. In particular, because this assay focuses on intermolecular proteolysis, it would increase the sensitivity for an initial weak inhibitor that might not be capable of out-competing an intramolecular event.

To our knowledge we present the first biochemical data that the prodomain itself acts as an inhibitor of proteolysis *in trans*. This is not surprising given that the PCSK9 structure suggests that the prodomain sterically inhibits access to the active site. The marked decrease in inhibition of intermolecular cleavage by a prodomain with a single C-terminal deletion (Δ Q152) further supports the steric hypothesis. However, additional truncations neither make the prodomain a less effective inhibitor nor disrupt binding to the catalytic domain, and as such it is tempting to speculate that another mechanism for this inhibition may be at play. We acknowledge that we have not conclusively addressed other possible mechanisms by which the truncated prodomain may affect the catalytic domain, including interference with proper folding, the formation of non-functional protein aggregates, or the binding of a motif other than the C-terminal tail that might compete against the intact prodomain of the substrate_{PCSK9}. Exogenous prodomain, in the form of a soluble chimeric prodomain-F_c(IgG1) fusion, has been shown to bind to mature PCSK9 independent of the CHR domain and disrupt the interaction with the LDL-R (38). Such an effect may be similar to what we are seeing here, although this remains speculation. As we ultimately chose to pursue the relationship of the prodomain to protein secretion, further evaluation of these mechanisms was outside the scope of this study.

Intriguingly, in our substrate alanine scan we found evidence of a disconnect between our intermolecular cleavage system and intramolecular proteolysis. Notably, our P3 mutant (F150A) does not undergo proteolysis, but our P3' mutant (P155A) does, which is essentially the reverse of what has previously been described for intramolecular proteolysis (16). We speculate that this disconnect relates to the method of presentation of the substrate_{PCSK9} to the active site of the protease. The turn induced by Pro-155 may be required to internally align the cleavage sequence with the substrate binding groove yet may be less important for an intermolecular presentation. Likewise, the π - π stacking interaction of Phe-150 with Trp-72 may be required to drive the initial recognition of the substrate_{PCSK9} with protease_{PCSK9 Δ Pro} but may be less important for an intramolecular process, which has a higher effective molarity to drive the hydrolysis.

Nevertheless, the development of our intermolecular proteolysis assay allowed us to probe the impact of specific point mutations on substrate cleavage while comparing the effects of these same mutations on protein secretion in an *in trans* assay that effectively bypassed the need for proteolysis. In this manner we specifically isolated the effects of each mutation on proteolysis and secretion and found that in certain cases the results were discordant. We specifically evaluated the effect of muta-

tions at Gln-152 because the histidine mutation at this residue has been found in a hypocholesterolemic clinical cohort (36). Biochemical characterization of Q152H has previously shown that this mutant hinders PCSK9 processing by causing decreased intramolecular cleavage, leading to an intracellular accumulation of unprocessed proPCSK9 that interferes with wild-type proPCSK9 processing, producing a dominant-negative effect (37). Our results confirm the findings of the previous work; the Q152H indeed hinders intramolecular processing, and in addition, those proPCSK9_{Q152H} species that manage to undergo cleavage are then subjected to an additional selection against secretion. Whether it is the proPCSK9_{Q152H} or the cleaved PCSK9_{Q152H} that is predominantly responsible for the dominant-negative effect remains outside the scope of this investigation but is certainly of interest.

Within the past two years two specific mediators of PCSK9 secretion have been identified: Sec24a (39) and sortilin (40). These findings lend support to the concept that PCSK9 secretion occurs in a highly regulated manner. A recent report has also suggested that the ectodomain of the LDL-R acts as a chaperone for PCSK9 folding and cleavage, increasing throughput from the proPCSK9 form to the cleaved mature form (41). Furthermore, mutations in the CHR domain, which do not affect self-proteolysis, have been noted to cause PCSK9 loss-of-function by interfering with the secretion pathway (42). Our findings build on this concept, showing that the active site and its adjacent residues can modulate both proteolysis and secretion independently. Indeed, the active site Ser-386 itself is a prime example; we suspect that the general improvement in the *in trans* secretion of prodomain mutants with the inactive protease_{PCSK9 Δ Pro-S386A}, as compared with active protease_{PCSK9 Δ Pro}, is related to improved folding of the S386A catalytic domain and subsequently improved prodomain affinity. In support of this hypothesis, we have noticed similar improvements in the yield of a heterologous bacterial expression system, which is not dependent on secretion, with the S386A mutant (data not shown). Whether the residues of the prodomain C-terminal tail are critical for mediating the interactions with Sec24a, sortilin, or the ectodomain of the LDL-R would be an informative next line of inquiry. Our mutants may also help to identify the components of the complexes, such as the putative "cargo receptor" for Sec24a, that mediate these specific secretory events. In so doing we may uncover additional targets for anti-hypercholesterolemic therapies.

The structural information we infer from these mutagenesis experiments may aid in the development of specific secretion inhibitors. Because of the proximity of our mutations to the active site as well as their marked effect on protein secretion, it is reasonable to suggest that a small molecule bound to the active site could serve as an allosteric modulator of the secretion apparatus. Although V149A mutations are expected to abolish a critical isopropyl group that projects into the PCSK9 substrate binding groove, the F150A mutation abolishes a π - π stacking interaction with Trp-72, which appears to be critical for intermolecular proteolysis but tolerated by the secretion machinery. Likewise, the proteolytic machinery appears to be at least somewhat tolerant of the histidine imidazole at position

152, whereas the secretory machinery is more tolerant of the isoleucine *sec*-butyl chain than a charged imidazole. Such differences may allow us to infer different structure-activity relationships upon scaffolds identified as either proteolysis or secretion inhibitors and help to tailor the chemistry of such scaffolds toward inhibiting one pathway *versus* another. Additionally, our data showing that the C-terminal alanine insertion after Gln-152 retained secretory activity in the *in trans* system regardless of proteolysis (Fig. 4, *D*, right, lane 10, compared with *E*, lane 10) is consistent with prior data showing that a V5 tag inserted after the prodomain C terminus acts similarly in this same system (29). Although we have not tested this C-terminal alanine insertion in either intramolecular or intermolecular proteolysis, these data do raise the question of whether additional mutations in the full-length PCSK9 protein could permit secretion despite precluding proteolysis, allowing for secretion of the proPCSK9 form. Such a mutant might allow for structural data to target the proPCSK9 species directly.

Although our initial goal was to search for a chemically feasible way to inhibit PCSK9 proteolysis, we have uncovered an additional therapeutic target that appears as promising as proteolytic inhibition. Our data suggesting the decoupling of secretion from proteolysis implies that there are two different intracellular stages at which to target PCSK9. Furthermore, an approach to specifically target secretion would theoretically have the same effect as targeting proteolysis; it would prevent PCSK9 from properly reaching the cell surface and interacting with the LDL-R. Although an intracellular mechanism of LDL-R degradation has been noted (43), it is clear from both parabiosis experiments (10) as well as the marked success of anti-PCSK9 antibodies in clinical trials (12, 13) that focusing on extracellular PCSK9 is a viable strategy. Because our data as well as that of others (37) suggest that inhibition of Q152H processing is in part mediated by a specific block on secretion, such a strategy would inch even closer to phenocopying this known genetic mutation. Given that this mutation is both dominant negative and is well tolerated (indeed, cardioprotective) in individuals, we see this as further encouragement for such an approach.

Acknowledgments—We thank Prof. J. Horton (UT Southwestern) for kindly providing the pCMV-PCSK9-FLAG plasmid and Dr. T. Shropshire and Prof. P. Daugherty for providing the pB33-newCyPET-LVPRGS(Sub)-YPET plasmid. We also thank Prof. Charles Craik, Dr. Anthony O'Donoghue, members of the Shokat laboratory, and the reviewers for helpful insights on the manuscript.

REFERENCES

- Park, S. W., Moon, Y.-A., and Horton, J. D. (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. *J. Biol. Chem.* **279**, 50630–50638
- Maxwell, K. N., and Breslow, J. L. (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 7100–7105
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat. Genet.* **34**, 154–156
- Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., and Hobbs, H. H. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat. Genet.* **37**, 161–165
- Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr., and Hobbs, H. H. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N. Engl. J. Med.* **354**, 1264–1272
- Tosi, I., Toledo-Leiva, P., Neuwirth, C., Naoumova, R. P., and Soutar, A. K. (2007) Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. *Atherosclerosis* **194**, 102–111
- Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. *Am. J. Hum. Genet.* **79**, 514–523
- Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nasoury, N., Mayer, H., Nimpf, J., Prat, A., and Seidah, N. G. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. *J. Biol. Chem.* **283**, 2363–2372
- McNutt, M. C., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., and Lagace, T. A. (2009) Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. *J. Biol. Chem.* **284**, 10561–10570
- Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. *J. Clin. Invest.* **116**, 2995–3005
- Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., and Deisenhofer, J. (2008) Molecular basis for LDL receptor recognition by PCSK9. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 1820–1825
- Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., and Swergold, G. D. (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. *N. Engl. J. Med.* **366**, 1108–1118
- Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsimsonis, K., Kim, J. B., Scott, R., Wasserman, S. M., Stein, E. A., DESCARTES Investigators. (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *N. Engl. J. Med.* **370**, 1809–1819
- Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., Nochur, S. V., Kotelianski, V., Horton, J., Mant, T., Chiesa, J., Ritter, J., Munisamy, M., Vaishnav, A. K., Gollob, J. A., and Simon, A. (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. *Lancet.* **383**, 60–68
- Seidah, N. G., Awan, Z., Chrétien, M., and Mbikay, M. (2014) PCSK9: a key modulator of cardiovascular health. *Circ. Res.* **114**, 1022–1036
- Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M. C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., Boileau, C., Brissette, L., Chrétien, M., Prat, A., and Seidah, N. G. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *J. Biol. Chem.* **279**, 48865–48875
- Naureckiene, S., Ma, L., Sreekumar, K., Purandare, U., Lo, C. F., Huang, Y., Chiang, L. W., Grenier, J. M., Ozenberger, B. A., Jacobsen, J. S., Kennedy, J. D., DiStefano, P. S., Wood, A., and Bingham, B. (2003) Functional characterization of Narc 1, a novel proteinase related to proteinase K. *Arch. Biochem. Biophys.* **420**, 55–67
- Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. *Proc. Natl. Acad. Sci.*

- U.S.A. **100**, 928–933
19. Nassoury, N., Blasiolo, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. *Traffic* **8**, 718–732
 20. Maxwell, K. N., Fisher, E. A., and Breslow, J. L. (2005) Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2069–2074
 21. Seidah, N. G., and Prat, A. (2012) The biology and therapeutic targeting of the proprotein convertases. *Nat. Rev. Drug Discov.* **11**, 367–383
 22. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman-Engwall, K. J., Warren, L. C., Xia, D., and Qiu, X. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. *Nat. Struct. Mol. Biol.* **14**, 413–419
 23. Kourimate, S., Chétiveaux, M., Jarnoux, A. L., Lalanne, F., and Costet, P. (2009) Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes. *Atherosclerosis* **206**, 134–140
 24. Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., and Walker, N. P. (2007) The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. *Structure* **15**, 545–552
 25. Rahuel, J., Rasetti, V., Maibaum, J., Rüeger, H., Göschke, R., Cohen, N. C., Stutz, S., Cumin, F., Fuhrer, W., Wood, J. M., and Grütter, M. G. (2000) Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. *Chem. Biol.* **7**, 493–504
 26. Maibaum, J., Stutz, S., Göschke, R., Rigollier, P., Yamaguchi, Y., Cumin, F., Rahuel, J., Baum, H. P., Cohen, N. C., Schnell, C. R., Fuhrer, W., Gruetter, M. G., Schilling, W., and Wood, J. M. (2007) Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. *J. Med. Chem.* **50**, 4832–4844
 27. Liu, H., and Naismith, J. H. (2008) An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. *BMC Biotechnol.* **8**, 91
 28. Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison, C. A., 3rd, and Smith, H. O. (2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat. Methods* **6**, 343–345
 29. McNutt, M. C., Lagace, T. A., and Horton, J. D. (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. *J. Biol. Chem.* **282**, 20799–20803
 30. Du, F., Hui, Y., Zhang, M., Linton, M. F., Fazio, S., and Fan, D. (2011) Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. *J. Biol. Chem.* **286**, 43054–43061
 31. Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., and Spraggon, G. (2007) The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 14604–14609
 32. Seidah, N. G., Sadr, M. S., Chrétien, M., and Mbikay, M. (2013) The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. *J. Biol. Chem.* **288**, 21473–21481
 33. Fu, X., Inouye, M., Shinde, U. (2000) Folding pathway mediated by an intramolecular chaperone. The inhibitory and chaperone functions of the subtilisin propeptide are not obligatorily linked. *J. Biol. Chem.* **275**, 16871–16878
 34. Anderson, E. D., VanSlyke, J. K., Thulin, C. D., Jean, F., and Thomas, G. (1997) Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage. *EMBO J.* **16**, 1508–1518
 35. Nguyen, A. W., and Daugherty, P. S. (2005) Evolutionary optimization of fluorescent proteins for intracellular FRET. *Nat. Biotechnol.* **23**, 355–360
 36. Mayne, J., Dewpura, T., Raymond, A., Bernier, L., Cousins, M., Ooi, T. C., Davignon, J., Seidah, N. G., Mbikay, M., and Chrétien, M. (2011) Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. *Clin. Chem.* **57**, 1415–1423
 37. Benjannet, S., Hamelin, J., Chrétien, M., and Seidah, N. G. (2012) Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. *J. Biol. Chem.* **287**, 33745–33755
 38. Saavedra, Y. G., Zhang, J., and Seidah, N. G. (2013) PCSK9 prosegment chimera as novel inhibitors of LDLR degradation. *PLoS ONE* **8**, e72113
 39. Chen, X.-W., Wang, H., Bajaj, K., Zhang, P., Meng, Z. X., Ma, D., Bai, Y., Liu, H. H., Adams, E., Baines, A., Yu, G., Sartor, M. A., Zhang, B., Yi, Z., Lin, J., Young, S. G., Schekman, R., and Ginsburg, D. (2013) SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. *Elife* **2**, e00444
 40. Gustafsen, C., Kjolby, M., Nyegaard, M., Mattheisen, M., Lundhede, J., Buttenschøn, H., Mors, O., Bentzon, J. F., Madsen, P., Nykjaer, A., and Glerup, S. (2014) The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. *Cell Metab.* **19**, 310–318
 41. Strøm, T. B., Tveten, K., and Leren, T. P. (2014) PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum. *Biochem. J.* **457**, 99–105
 42. Cameron, J., Holla, Ø. L., Laerdahl, J. K., Kulseth, M. A., Berge, K. E., and Leren, T. P. (2009) Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage. *Atherosclerosis* **203**, 161–165
 43. Poirier, S., Mayer, G., Poupon, V., McPherson, P. S., Desjardins, R., Ly, K., Asselin, M. C., Day, R., Duclos, F. J., Witmer, M., Parker, R., Prat, A., and Seidah, N. G. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. *J. Biol. Chem.* **284**, 28856–28864

The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis

John S. Chorba and Kevan M. Shokat

J. Biol. Chem. 2014, 289:29030-29043.

doi: 10.1074/jbc.M114.594861 originally published online September 10, 2014

Access the most updated version of this article at doi: [10.1074/jbc.M114.594861](https://doi.org/10.1074/jbc.M114.594861)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 43 references, 19 of which can be accessed free at <http://www.jbc.org/content/289/42/29030.full.html#ref-list-1>